Aminomethylbenzoic Acid

Perioperative bleeding is a common complication in surgical procedures, which can lead to patient shock or even death in severe cases. Antifibrinolytic drugs are one of the core medications for controlling this type of bleeding. Aminomethylbenzoic acid is a synthetic antifibrinolytic drug. It competitively blocks the binding of plasminogen to fibrin, inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and exerting a hemostatic effect. Clinically, it is mainly used for bleeding caused by excessive primary fibrinolysis, including acute and chronic, localized or systemic hyperfibrinolytic bleeding, which is commonly seen in cancer, leukemia, obstetrics and gynecology accidents, bleeding from severe liver diseases, etc. It can also be used for traumatic or surgical bleeding from organs rich in plasminogen activators such as the prostate, urethra, lung, liver, etc. It is a basic and commonly used drug in the field of hemostasis.

The domestic hemostatic drug market size has exceeded 30 billion yuan, of which antifibrinolytic drugs account for approximately 18%. As a basic hemostatic drug recommended by clinical pathways, the market demand for aminomethylbenzoic acid is stable in the annual sales range of 400 million to 500 million yuan. This drug was developed at an early stage, and all its patents have expired. Currently, the domestic market is dominated by generic drug supplies, with more than 20 manufacturers, and the overall competition is sufficient. Affected by the volume-based procurement policy, the price of preparations has dropped by more than 60%, driving the demand for upstream APIs to concentrate on leading suppliers with stable production capacity and compliant quality.

There is no clear original research enterprise for aminomethylbenzoic acid. It was first developed and marketed by foreign pharmaceutical companies and then widely used worldwide. Currently, the main dosage forms of domestically approved aminomethylbenzoic acid preparations are injections (5ml:50mg, 10ml:0.1g) and tablets (0.125g, 0.25g). Relevant dosage forms have been included in the National Essential Medicines List, and preparations from multiple manufacturers are listed as reference listed drugs. In terms of APIs, there are more than 30 A-status registration numbers for aminomethylbenzoic acid in China, which can be used in association with preparation declarations. The domestically approved marketed preparation varieties cover the two commonly used dosage forms of injection and tablet, with sufficient supply. (Data as of October 2025, please refer to the official CDE website for the latest information.)

CATO can provide a full set of impurity reference standards for aminomethylbenzoic acid API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, fully meeting the needs of pharmaceutical enterprises for quality research, registration and declaration, as well as daily production quality control.